Pheton Holdings Ltd Class A Ordinary Shares (PTHL) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Pheton Holdings Ltd Class A Ordinary Shares (PTHL) trades at $0.2815 with AI Score 51/100 (Grade B). iTonic Holdings Ltd. Market cap: $4.09M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for PTHL: PTHL does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PTHL against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
PTHL: 1/3 scored disciplines lean bearish. Dominant signal: Jim Simons bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Pheton Holdings Ltd Class A Ordinary Shares (PTHL) Healthcare & Pipeline Overview
iTonic Holdings Ltd., based in Beijing, specializes in brachytherapy solutions, offering the FTTPS treatment planning system for precise cancer radiotherapy. The company's focus on radioactive particle implantation positions it within the niche medical device market, serving healthcare providers treating various malignant tumors with targeted radiation therapy.
What Is the Investment Thesis for PTHL?
iTonic Holdings Ltd. presents a focused investment opportunity within the brachytherapy segment of the medical device industry. With a gross margin of 82.9%, the company showcases strong potential for profitability. However, a negative ROE of -101.6% indicates current challenges in generating returns on equity. The company's debt-to-equity ratio of 2.95 suggests a reliance on debt financing. A beta of 1.00 indicates market correlation. The primary value driver lies in the continued adoption of the FTTPS treatment planning system by healthcare providers. Growth catalysts include expanding the application of FTTPS to treat a wider range of malignant tumors and securing regulatory approvals in new geographic markets. Investors should closely monitor the company's ability to improve its ROE and manage its debt levels effectively.
Based on FMP financials and quantitative analysis
PTHL Key Highlights
Gross Margin of 82.9% indicates strong pricing power and efficient cost management in the production of brachytherapy solutions.
- Negative ROE of -101.6% signals potential challenges in generating profits from shareholder equity, requiring further investigation into operational efficiency.
- Debt-to-Equity Ratio of 2.95 suggests a relatively high level of financial leverage, indicating reliance on debt financing.
- Free Cash Flow of $-0.00B indicates the company is not currently generating positive free cash flow, which may impact its ability to fund future growth initiatives.
- Beta of 1.00 suggests the stock's price movements are expected to align with the overall market volatility.
Who Are PTHL's Competitors?
PTHL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| VAR VAR | $177.07 | +0.00% | 46 | |
| CNVIF Conavi Medical Corp. | $0.13 | -1.19% | $11.4M | 66 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.07 | -4.02% | $13.8M | 62 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PLSM PLSM | $2.96 | -1.66% | $19.3M | 60 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.27 | -1.08% | $24.6M | 73 |
| RDGL Vivos Inc. | $0.05 | -5.33% | $26.5M | 61 |
| NVYTF Novacyt S.A. | $0.48 | -0.00% | $34.8M | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PTHL's Key Strengths?
Proprietary FTTPS treatment planning system
- Specialized expertise in brachytherapy
- High gross margin (82.9%)
- Established presence in the Chinese market
What Are PTHL's Weaknesses?
Negative ROE (-101.6%)
- High debt-to-equity ratio (2.95)
- Limited geographic diversification
- Small number of employees (10)
What Could Drive PTHL Stock Higher?
Regulatory approvals for FTTPS in new geographic markets.
- Expansion of FTTPS applications to treat additional types of cancer.
- Strategic partnerships with hospitals and cancer centers to promote FTTPS adoption.
- Continuous product innovation and development of advanced features for FTTPS.
What Are the Key Risks for PTHL?
Negative return on equity (-93.9%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from larger medical device companies with greater resources.
- Regulatory hurdles and delays in obtaining approvals for FTTPS.
- Technological advancements in alternative radiation therapy techniques.
- Economic downturns and healthcare budget constraints impacting demand for brachytherapy solutions.
- High debt-to-equity ratio potentially limiting financial flexibility.
What Are the Growth Opportunities for PTHL?
- Expanding FTTPS Applications: iTonic Holdings Ltd. can expand the application of its FTTPS treatment planning system to cover a broader range of malignant tumors. The global radiation oncology market is projected to reach $9.7 billion by 2027, offering a substantial market opportunity. By securing regulatory approvals for new tumor types and demonstrating the clinical efficacy of FTTPS, the company can increase its market share and revenue streams. Timeline: 2-3 years for regulatory approvals and clinical trials.
- Geographic Expansion: iTonic Holdings Ltd. can pursue geographic expansion by entering new markets in Asia, Europe, and North America. The increasing prevalence of cancer globally drives the demand for advanced radiation therapy solutions. By establishing partnerships with local distributors and obtaining necessary regulatory approvals, the company can access new customer bases and diversify its revenue streams. Timeline: 3-5 years for market entry and penetration.
- Strategic Partnerships: iTonic Holdings Ltd. can form strategic partnerships with hospitals, cancer centers, and research institutions to promote the adoption of its FTTPS system. Collaborating with key opinion leaders and participating in clinical trials can enhance the credibility and visibility of the company's technology. These partnerships can also facilitate the integration of FTTPS into existing treatment protocols and workflows. Timeline: 1-2 years for partnership agreements and implementation.
- Product Innovation: iTonic Holdings Ltd. can invest in research and development to enhance the capabilities of its FTTPS system and introduce new features. Developing advanced algorithms for dose optimization and incorporating artificial intelligence for treatment planning can improve the accuracy and efficiency of brachytherapy procedures. Continuous product innovation can strengthen the company's competitive advantage and attract new customers. Timeline: Ongoing, with iterative improvements and new releases.
- Training and Education Programs: iTonic Holdings Ltd. can offer comprehensive training and education programs for medical professionals on the use of its FTTPS system. Providing hands-on training, online resources, and certification programs can enhance the skills and confidence of healthcare providers in utilizing brachytherapy techniques. These programs can also foster long-term relationships with customers and promote the adoption of the company's technology. Timeline: Ongoing, with regular training sessions and educational materials.
What Are PTHL's Competitive Advantages?
- Proprietary FTTPS treatment planning system.
- Specialized expertise in brachytherapy solutions.
- Established relationships with hospitals and cancer centers.
What Does PTHL Do?
Founded in 1998 and headquartered in Beijing, China, iTonic Holdings Ltd. (PTHL) operates as a healthcare solutions provider focused on the development and commercialization of treatment software and devices for brachytherapy. Brachytherapy involves placing radioactive sources inside a patient's body to kill cancer cells and shrink tumors. PTHL's core product is the FTTPS treatment planning system, designed to assist medical professionals in planning and executing brachytherapy procedures. The FTTPS system helps determine the target volume, prescription dose, and dose limitations to protect organs at risk, ultimately producing a dose distribution plan tailored for each cancer patient. As a subsidiary of ZJW (BVI) LTD, iTonic Holdings Ltd. caters to healthcare providers treating malignant tumors, offering a specialized solution for precise and targeted radiation therapy. The company's focus on brachytherapy positions it within a niche segment of the broader medical devices market, emphasizing innovation in cancer treatment technologies.
What Products and Services Does PTHL Offer?
- Develops treatment planning software for brachytherapy.
- Commercializes devices used in radioactive particle implantation.
- Offers FTTPS, a treatment planning system for malignant tumors.
- Provides solutions for determining target volume and prescription dose.
- Aids in dose limitation to protect organs at risk during radiotherapy.
- Creates dose distribution plans for brachytherapy.
How Does PTHL Make Money?
- Generates revenue through the sale of FTTPS treatment planning system licenses.
- Provides maintenance and support services for its software and devices.
- Offers training and education programs for medical professionals using its products.
What Industry Does PTHL Operate In?
iTonic Holdings Ltd. operates within the medical device industry, specifically focusing on brachytherapy solutions for cancer treatment. The global medical devices market is experiencing steady growth, driven by an aging population, increasing prevalence of chronic diseases, and technological advancements. The brachytherapy segment is a specialized area within radiation oncology, offering targeted treatment options. Competition includes companies providing alternative radiation therapy techniques and treatment planning systems. iTonic Holdings Ltd.'s success depends on its ability to innovate and differentiate its FTTPS system in this competitive landscape.
Who Are PTHL's Key Customers?
- Hospitals and cancer centers
- Radiation oncologists
- Medical physicists
Company Profile
Pheton Holdings Ltd Class A Ordinary Shares operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Beijing, CN. The company is led by CEO Jianfei Zhang. PTHL has traded publicly since 2024.
Pheton Holdings Ltd Class A Ordinary Shares Financial Trajectory
Pheton Holdings Ltd Class A Ordinary Shares (PTHL) reported $68K in revenue for Q2 2025, a decline of 71.6% compared to the prior quarter. The company recorded a net loss of $2.0M, with diluted EPS of $-0.14. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare.
How Pheton Holdings Ltd Class A Ordinary Shares Is Valued
Pheton Holdings Ltd Class A Ordinary Shares carries a market capitalization of $4.09M, placing it in the micro-cap category. Relative to its peer group, PTHL's quantitative score of 51/100 is roughly in line with the peer average of 60/100.
Key Financial Metrics
Return on equity for Pheton Holdings Ltd Class A Ordinary Shares stands at -93.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -56.0%, showing how much profit it generates from its asset base. A current ratio of 8.83 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -98.5%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Pheton Holdings Ltd Class A Ordinary Shares's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 4.90 places it in the safe zone, indicating low near-term bankruptcy risk.
PTHL Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Proprietary FTTPS treatment planning system
- Specialized expertise in brachytherapy
- High gross margin (82.9%)
- Established presence in the Chinese market
Bear Case
- Negative ROE (-101.6%)
- High debt-to-equity ratio (2.95)
- Limited geographic diversification
- Small number of employees (10)
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | $67,507 | -$2M | -$0.14 |
| Q4 2024 | $237,708 | -$375,456 | -$0.03 |
| Q2 2024 | $210,488 | -$285,132 | -$0.02 |
Based on FMP financials and quantitative analysis
PTHL Latest News
No recent news available for PTHL.
PTHL Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PTHL.
Price Targets
Wall Street price target analysis for PTHL.
PTHL MoonshotScore
What does this score mean?
The MoonshotScore rates PTHL 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Common Questions About PTHL (Healthcare)
What does the AI Score mean for PTHL?
PTHL holds an AI Score of 51/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. iTonic Holdings Ltd. (PTHL) develops and commercializes treatment software and devices for brachytherapy, a radiotherapy method using radioactive sources to treat cancer. Their proprietary …
What does iTonic Holdings Ltd. do?
iTonic Holdings Ltd. specializes in providing healthcare solutions through the development and commercialization of treatment software and devices for brachytherapy, a form of radiotherapy. Their flagship product, the FTTPS treatment planning system, is designed to assist medical professionals in planning and executing brachytherapy procedures for cancer patients.
What are the key growth opportunities for PTHL in healthcare?
iTonic Holdings Ltd. has several growth opportunities within the healthcare sector. These include expanding the application of its FTTPS system to treat a wider range of malignant tumors, securing regulatory approvals in new geographic markets, forming strategic partnerships with hospitals and research institutions, and investing in product innovation to enhance the capabilities of its FTTPS system.
What are the main risks for PTHL?
iTonic Holdings Ltd. faces several risks, including competition from larger medical device companies with greater resources, regulatory hurdles and delays in obtaining approvals for its FTTPS system, technological advancements in alternative radiation therapy techniques, and economic downturns and healthcare budget constraints impacting demand for brachytherapy solutions.
What are the key factors to evaluate for PTHL?
Pheton Holdings Ltd Class A Ordinary Shares (PTHL) holds an AI score of 51/100 (moderate). iTonic Holdings Ltd. Not financial advice.
How frequently does PTHL data refresh on this page?
PTHL's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PTHL's recent stock price performance?
Pheton Holdings Ltd Class A Ordinary Shares (PTHL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary FTTPS treatment planning system. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PTHL overvalued or undervalued right now?
Pheton Holdings Ltd Class A Ordinary Shares (PTHL) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PTHL before investing?
Before investing in Pheton Holdings Ltd Class A Ordinary Shares (PTHL), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data may be limited due to the company's size and reporting requirements.
- AI analysis is pending, which may provide further insights into the company's performance and outlook.